Purpose: The chromosomal deletion 11q affects biology and clinical outcome in CLL but del11q-deregulated genes remain incompletely characterized.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in the Western world, and is characterized by a highly variable clinical course (1) . CLL is heterogeneous, and several disease-related factors have been identified that classify CLL into biologically distinct and clinically relevant subtypes. Lack of mutations in the immunoglobulin heavy-chain variable-region (IgV H ) genes, increased expression of zetaassociated protein of 70kDa (ZAP-70), presence of del17p/p53 aberrations, del11q, and elevated genomic complexity are some of the molecular parameters which have been associated with an aggressive disease course, shortened disease-free intervals, or compromised survival . It is likely that additional factors will be identified that have an effect on CLL biology and clinical behavior, particularly in disease subsets.
Interstitial deletions on the long arm of chromosome 11 (del11q) occur in ~15-20% of all CLL and have been associated with relatively more progressive and aggressive CLL.
Given that a comprehensive view of del11q-associated molecular deregulations has not yet emerged, and given the importance of del11q in CLL clinical outcome, studies into the mechanisms of del11q-associated phenotypes in CLL seemed warranted. One of the genes implicated in del11q-associated biology in CLL is ATM, which is mono-allelically deleted through all 11q deletions that are defined through the clinically used 11q FISH probe (24) (25) (26) .
Mutations in ATM have been identified on the retained allele in a minority subset of CLL with del11q, and CLL cases with del11q and mutated ATM have been proposed to have a more aggressive disease course than CLL cases with del11q and wildtype ATM (27, 28) . As it has been observed that ATM mutations in the setting of del11q are acquired as part of CLL evolution, it is not likely that ATM-null states drive initial CLL disease progression. Thus the Author Manuscript Published OnlineFirst on February 9, 2011; DOI: 10.1158/1078-0432.CCR- molecular drivers of CLL disease progression in general and in the setting of 11q deletions in particular remain incompletely understood. One such driver may be TCL1, which is often expressed at relatively high levels in CLL cells with del11q and has been proposed as a contributor to B-cell receptor responsiveness and CLL disease progression (29) . Very little additional information is available about del11q-linked biology in CLL, and a molecular explanation as to why CLL cells would select for interstitial deletions on 11q (in the absence of prior therapy) has not been advanced.
In this study, we have used integrated genomic profiling approaches to identify stable transcriptome differences that exist between CLL with and without del11q. Array-based transcriptome analysis identified, for the first time, increased and preferential expression of the INSR in CLL with del11q, a finding that was validated in a large cohort of highly characterized CLL cases. INSR expression was found at varying absolute levels in CLL and and written informed consent was obtained from all patients prior to enrollment. INSR data from 257 of these 267 patients were included in this analysis (5 patients enrolled on the study were excluded from analysis due to a diagnosis that was not CLL, and 5 patients had insufficient cryopreserved cells available).
Regardless of whether the subjects were originally diagnosed at our institution or another, we used the same CLL diagnostic criteria, based on the National Cancer InstituteWorking Group Guidelines for CLL (30) . Eligible patients needed to have an absolute lymphocytosis (greater than 5000 mature lymphocytes per µl), and lymphocytes needed to express CD19, CD23, sIg (weak) and CD5 in the absence of other pan-T-cell markers.
Time to first therapy (TTFT) and overall survival (OS) were based on the CLL diagnosis date as previously defined (6) . CLL treatment was defined as cytotoxic chemotherapy and/or monoclonal antibody therapy for CLL. Clinical information, including Rai stage; lymph node size and serial absolute lymphocyte count (ALC) measurements (at least 3) at the time of enrollment; and all treatments given was collected on all patients.
Patient samples were characterized for selected CLL-associated chromosomal aberrations as a routine clinical test at the Mayo Clinic using FISH, as previously described (6) . Nineteen selected CLL samples (see Supplementary Table 1) were sorted to purity using a high-speed FACSAria (Becton Dickinson) sorter and RNA extracted using the Trizol reagent. RNA was further purified using the RNeasy kit (Qiagen). 50ng total RNA was amplified using the Ovation RNA Amplification system (NuGen, Inc.), labeled with the FLOvation cDNA Biotin module (NuGen, Inc.) and hybridized to the Human 133 2.0 Plus GeneChip (Affymetrix) following the manufacturer's recommended protocols.
Affymetrix GeneChip data were analyzed as described (31) . Raw probe-level data were converted to expression measures using the Robust Multi-array Average (RMA)
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Author Manuscript Published OnlineFirst on February 9, 2011; DOI: 10.1158/1078-0432.CCR- method, which is implemented in the Affymetrix package of Bioconductor (32) . Briefly, the raw perfect match (PM) probes are first quartile normalized to reduce array-to-array variation. The normalized probe data are then converted to an expression measure (log scale) for each gene on each chip. For differential expression analysis relating to 11q deletion status, we used two-sample Z-tests to compare the mean log-scale expression level between del11q and non-del11q samples. Genes with a False Discovery Rate (33) below 0.1 were selected, then fold-changes, FDR values, and Z-scores were used to identify genes having a strong association with 11q deletion status. There were 83 probe sets meeting this criterion. These probe sets are listed in Table 1 , sorted by significance levels. Expression array data have been deposited with GEO (GEO # pending). 
Measurement of Gene Expression using Q-PCR

FACS-based measurements of INSR expression in CLL
CLL samples were thawed in a 37°C water bath, added dropwise into prewarmed RPMI medium with 10% heat-inactivated fetal calf serum (FCS), centrifuged, and washed 
Measurements of radiation-induced ATM autophosphorylation in CLL
Measurements of radiation-induced ATM autophosphorylation in CLL were performed as previously reported (34) . FACS-sorted CD19+ and CD3+ cells were digested overnight in 100 mM Tris pH 8.0, 50 mM EDTA, 50 mM NaCl, 0.5% SDS and 100 μg/ml of Proteinase K (Invitrogen) at 56 0 C.
DNA was extracted using phenol-chloroform and precipitated using ammonium acetate, ethanol and glycogen. DNA was prepared for hybridization to SNP 6.0 arrays according to the manufacturers' recommendations. Sample copy number heatmap displays were obtained from CEL files through use of the freely available software dChip adapted to operate in a 64-bit environment(35) as described (36) .
Methods used for CLL outcome analysis
Event times (TTFT, OS) were recorded in months, along with an indicator of whether the event was reached, or the time was censored. Ninety-eight percent of censoring reflects the current status at the date of analysis rather than loss to follow-up. To explore the relationship between INSR expression and outcomes, we considered various thresholds that can be used to partition the sample into two groups (high/low INSR expression). The hazard ratio for an outcome (e.g. TTFT) can then be estimated using proportional hazards models.
The hazard ratio and the p-value for the null hypothesis that the hazard ratio differs from one (indicating equal hazards in the two groups) are displayed as functions of the threshold. 
RESULTS
Patient Characteristics
Data from 257 unselected CLL patients (of which 79% were untreated and 21% previously treated [median number of prior treatments =1] at study enrollment) that were consecutively enrolled at the University of Michigan between January 2005 and October 2009 were included in this analysis. Outcome analysis was performed as reported using the date of CLL diagnosis as the reference date(6).
The insulin receptor is expressed in a subset of CLL cases, with preferential expression in CLL with deletion 11q.
Comparative array-based transcriptome analysis between 10 CLL cases with and 9 cases without del11q (all centered on 11q22 and always inclusive of ATM) resulted in 83 probe sets measuring differential gene expression between the two groups at a false discovery rate of <0.1 (33) . The majority of the associated genes physically mapped to 11q21-23 and all indicated lower expression in CLL with del11q21-23 than CLL without del11q21-23, providing confidence in our assay conditions (Table 1) . Twenty-five probe sets representing 22 differentially expressed genes were not located within del11q21-23; among these, multiple sets identified substantially higher INSR expression (log 2 -fold differences of 2.52, 3 and 3.15) in CLL with del11q21-23 as opposed to the reference cases ( and plotted normalized INSR expression for each case according to genomic CLL subtype.
As can be seen in Figure 1A , INSR mRNA expression in CLL covered a wide range and INSR mRNA was expressed at detectable levels in ~50-60% of all CLL cases. INSR expression was absent in ~40% of all CLL. Importantly, CLL cases that carried del11q as measured through FISH (using a probe centered on ATM) had significantly and many fold (~10-fold) higher INSR mRNA levels than all other FISH-based CLL subgroups (the mRNA data in Figure 1A are on a ~log 2 -fold scale) and many non-del11q CLL cases did not Attempting to explain why some cases of CLL with 11q deletions did not express the INSR at high levels, we mapped 11q deletions in this cohort using SNP 6.0 ultra-highresolution arrays and correlated the del11q anatomy with INSR mRNA and protein levels.
As can be seen in Figure 3A -B, the position or length of 11q deletions alone is insufficient to explain the observed INSR expression differences. Furthermore, the INSR gene was not amplified.
ATM activity does not correlate with INSR expression
Given the strong enrichment of CLL cases with del11q amongst the CLL with high at Ser-389 and S6-ribosomal protein at residues 235/236. Finally, in 7/14 cases, we detected increased insulin-induced Erk1/2 phosphorylation at residues Thr202/Tyr204 while the remaining cases demonstrated elevated baseline Erk1/2 phosphorylation (activation) states, as previously described (38) .
Given that IRS-1 is a central INSR signaling node, we investigated insulin-induced
IRS-1 phosphorylation on tyrosine in enriched CD19+ CLL cells stimulated with 10nM
insulin. IRS-1 was immunoprecipitated from stimulated and unstimulated lysates, protein was fractioned by SDS-PAGE and then transferred to membrane. Tyrosine phosphorylation was detected using the anti-phosphotyrosine-specific antibody 4G10. As can be seen in 
INSR expression is associated with rapid initial disease progression in CLL with <20%
ZAP-70 expression (bivariate analyses).
ZAP-70 expression identifies a CLL subgroup that progresses to need of first therapy (TTFT) within 3-4 years, and thus ZAP-70 expression constitutes one of the strongest predictors of progressive CLL(5). We therefore performed bivariate analyses to detect effects of INSR expression (at various thresholds) on TTFT and OS in the setting of known ZAP-70 status. As can be seen in Figure 6A Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Table 1 : List of differentially expressed genes between CLL cases with and without deletion 11q, ranked by significance levels at a FDR of <0.1. 
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